The Latest Cardiac and Vascular News
CAMZYOS is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the underlying source of obstructive HCM VALOR-HCM is the second Phase 3 trial in which CAMZYOS demonstrated significant improvement in symptoms of obstructive HCM June 15, 2023 08:23 PM Eastern Daylight Time PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced […]
Verve to Receive $60 Million in Combined Upfront Payment and Equity Investment; Additional Capital Positioned to Extend Verve’s Expected Cash Runway into 2026 Verve has Opt-in Rights to Co-fund and Share in Potential Margins of Products Resulting from the Collaboration BOSTON, June 15, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. […]
PRINCETON, N.J., June 15, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has received the recommendation from the independent Data and Safety Monitoring Board […]
IRVIVE, Calif., June 14, 2023 /PRNewswire/ — Cardiovascular health technology company, CardieX Limited, is pleased to announce it has been selected as part of MedTech Innovator’s 2023 Accelerator Cohort. MedTech Innovator is recognized as the world’s largest accelerator of medical technology companies. More than 1,150 companies applied to participate in the 2023 Accelerator program […]
Novel Polymeric Valve Aims to Reduce Re-operations and Re-interventions PITTSBURGH–(BUSINESS WIRE)–PECA Labs, a medical device company reimagining vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, today announced the successful first-in-human implant of the MASA Valve. Designed for pediatrics, the MASA Valve is a […]
Developed in collaboration with REPROCELL, CELLvo™ Atrial Cardiomyocyte delivers non-genetically modified human heart cells that are chamber specific and derived from iPS (stem) cells SAN ANTONIO, June 13, 2023 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) announced today the launch of CELLvo™ Atrial Cardiomyocyte, a “chamber specific” human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to […]
AdventHealth Orlando performs their first implant of Guardian™ System, revolutionizing cardiac care in Central Florida EATONTOWN, N.J. and ORLANDO, Fla., June 13, 2023 (GLOBE NEWSWIRE) — Avertix Medical, Inc. (“Avertix” or the “Company”), formerly known as Angel Medical Systems, Inc., a company focused on improving long-term management and outcomes of high-risk coronary […]
LX2006 is the first investigational gene therapy for the treatment of Friedreich’s ataxia cardiomyopathy Initial data from the first two cohorts, including myocardial protein expression and biomarkers measuring serum and cardiac structure and function, expected in the first half of 2024 NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) — LEXEO Therapeutics (LEXEO), […]
SSi Mantra System now Clinically Validated in More Than 35 Different Surgical Procedures FORT LAUDERDALE, FL, June 13, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to […]
The study represents a significant breakthrough in understanding the potential for reversing and measuring epigenetic changes associated with coronary heart disease after therapeutic intervention June 13, 2023 09:01 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, announced the […]
